Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (601-610 of 709) with videos related to

Pageof 71
Sort By:
Cancer Medicine|January 22, 2020
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Shigeyoshi Iwamoto, et al.
BMC Cancer|June 28, 2022
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Akihito Tsuji, et al.
Digestion|January 16, 2023
Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC TrialRyo Ohta, Takeshi Yamada, Masato Nakamura, et al.
International Journal of Oncology|May 13, 2015
Establishment of patient-derived cancer xenografts in immunodeficient NOG miceTsuyoshi Chijiwa, Kenji Kawai, Akira Noguchi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 25, 2006
Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alphaHiroshi Wada, Hiroaki Nagano, Hirofumi Yamamoto, et al.
BMC Cancer|November 14, 2019
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinomaTakahiro Maeda, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.
The Lancet. Oncology|November 15, 2013
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trialYasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, et al.
Cardiovascular Intervention and Therapeutics|July 19, 2022
Clinical expert consensus document on standards for lower extremity artery disease of imaging modality from the Japan Endovascular Treatment ConferenceMasahiko Fujihara, Naoya Kurata, Yuko Yazu, et al.
Investigational New Drugs|September 12, 2017
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatmentSadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, et al.
Nature Geoscience|June 12, 2018
Equatorial jet in the lower to middle cloud layer of Venus revealed by AkatsukiTakeshi Horinouchi, Shin-Ya Murakami, Takehiko Satoh, et al.
Pageof 71

Showing results (601-610 of 709) with videos related to

Sort By:
Pageof 71
Cancer Medicine|January 22, 2020
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Shigeyoshi Iwamoto, et al.
BMC Cancer|June 28, 2022
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Akihito Tsuji, et al.
Digestion|January 16, 2023
Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC TrialRyo Ohta, Takeshi Yamada, Masato Nakamura, et al.
International Journal of Oncology|May 13, 2015
Establishment of patient-derived cancer xenografts in immunodeficient NOG miceTsuyoshi Chijiwa, Kenji Kawai, Akira Noguchi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 25, 2006
Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alphaHiroshi Wada, Hiroaki Nagano, Hirofumi Yamamoto, et al.
BMC Cancer|November 14, 2019
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinomaTakahiro Maeda, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.
The Lancet. Oncology|November 15, 2013
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trialYasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, et al.
Cardiovascular Intervention and Therapeutics|July 19, 2022
Clinical expert consensus document on standards for lower extremity artery disease of imaging modality from the Japan Endovascular Treatment ConferenceMasahiko Fujihara, Naoya Kurata, Yuko Yazu, et al.
Investigational New Drugs|September 12, 2017
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatmentSadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, et al.
Nature Geoscience|June 12, 2018
Equatorial jet in the lower to middle cloud layer of Venus revealed by AkatsukiTakeshi Horinouchi, Shin-Ya Murakami, Takehiko Satoh, et al.
Pageof 71